Author Interviews, Diabetes, Weight Research / 27.04.2023
ADA Statement Regarding Lilly’s Announcement of Weight Loss in Adults with Obesity and Type 2 Diabetes with Tirzepatide (Mounjaro™) Injections
Statement from Dr. Robert Gabbay, Chief Scientific and Medical Officer for the ADA, regarding the Lilly statement this of April...